Psoriatic Arthritis News

Glucocorticoid use, older age, male sex and comorbidity burden are among the predictors of more severe COVID-19 in patients with psoriasis, psoriatic arthritis or axial spondyloarthritis, according to data.

The FDA has approved a citrate-free, high-concentration formulation of the adalimumab biosimilar Hyrimoz, according to a press release from the manufacturer.

Mandatory switching policies for biosimilars are “much more” effective in increasing adoption than focusing on new start strategies, according to a study of Canadian health spending data published in Arthritis Care & Research.

There are key sex-specific differences in how psoriatic arthritis manifests in patients, with women reporting worse outcomes and treatment response compared with men, according to a review published in The Journal of Rheumatology.

SCOTTSDALE, Ariz. — SAPHO is complex, but knowing its potential manifestations can help clinicians identify and help patients, according to a speaker at the Basic and Clinical Immunology for the Busy Clinician meeting.

SCOTTSDALE, Ariz. — Understanding patients’ disease burden and priorities can help rheumatologists choose the best therapy for psoriatic arthritis, noted a speaker at the Basic and Clinical Immunology for the Busy Clinician symposium.

The 2-year safety profile of guselkumab appears consistently favorable across patients with psoriatic arthritis who are either naïve or experienced with TNF inhibitors, according to data published by The Journal of Rheumatology.

WAILEA, Hawaii — Patients with psoriatic arthritis treated with guselkumab for 6 months experienced a significant improvement in joint disease, skin disease and pain, according to a poster presented at the Maui Derm meeting.

WAILEA, Hawaii — Bolstered by Mendelian randomization studies linking coronary artery disease and psoriasis, researchers are exploring how to combat cardiovascular events in patients with psoriatic disease, according to a presenter here.